Longbow Capital

Galatea Technologies specializes in developing a platform that enhances logistics and decision-making processes within the oilfield waste sector. Its primary product, Waste Coordinator, is a software-as-a-service (SaaS) solution that automates and optimizes transportation workflows. This platform facilitates the effective management of waste, water, and emulsion loads by digitizing operations and providing intelligent scheduling and logistics optimization. By automating foundational workflows, Galatea Technologies enables users to maximize operational efficiency, financial performance, and environmental sustainability. Furthermore, it allows users to utilize and market excess capacity at disposal facilities while ensuring compliance with regulatory requirements through digital waste manifesting.

Ambicare Health Ltd specializes in developing wearable light sources for medical and consumer healthcare applications. The company offers innovative products such as Ambulight PDT, a light-emitting sticking plaster designed for treating non-melanoma skin cancer using photodynamic therapy, which serves as a non-surgical alternative. Additionally, Ambicare Health provides blue light therapy solutions, including Lustre Pure Light Classic and Lustre Pure Light Pro, which are effective in combating spots and acne. These products are distributed through various channels, including online sales and partnerships with distributors. Founded in 2004 and based in Livingston, United Kingdom, Ambicare Health was formerly known as Lumicure Ltd before rebranding in 2009.

Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.

Calon Cardio-Technology Ltd specializes in the development of implantable micro blood pumps aimed at treating chronic heart failure. The company offers several innovative products, including the MiniVAD, a miniature pump designed to be implanted in the left ventricle of the heart, which helps improve blood supply and alleviate the symptoms associated with heart failure. Additionally, Calon provides the MicroVAD, intended for earlier intervention in patients experiencing progressive heart failure, and the CathVAD, a catheter-delivered micro-pump for managing acute heart failure. Founded in 2007 and based in Swansea, United Kingdom, Calon Cardio-Technology focuses on enhancing patient outcomes through minimally invasive surgical procedures that facilitate the treatment of heart failure.

A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used, initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics.

Ambicare Health Ltd specializes in developing wearable light sources for medical and consumer healthcare applications. The company offers innovative products such as Ambulight PDT, a light-emitting sticking plaster designed for treating non-melanoma skin cancer using photodynamic therapy, which serves as a non-surgical alternative. Additionally, Ambicare Health provides blue light therapy solutions, including Lustre Pure Light Classic and Lustre Pure Light Pro, which are effective in combating spots and acne. These products are distributed through various channels, including online sales and partnerships with distributors. Founded in 2004 and based in Livingston, United Kingdom, Ambicare Health was formerly known as Lumicure Ltd before rebranding in 2009.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.

BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in 2007. The company was incorporated in 2006 and is based in London, the United Kingdom.

Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatory conditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need.

Destiny Pharma is a clinical-stage biotechnology company based in Brighton, United Kingdom, specializing in the discovery and development of innovative antimicrobial medicines aimed at treating infectious diseases. The company is advancing several drug candidates, including XF-73 Nasal, currently in Phase II trials for preventing post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I trials for treating skin infections caused by antibiotic-resistant bacteria. Additionally, Destiny Pharma is developing XF-70 for conditions such as ventilator-associated pneumonia and cystic fibrosis, along with DPD-207 for bacterial and fungal eye infections. The company collaborates with various academic institutions and organizations, including the University of Southampton and China Medical System Holdings Limited, to explore new treatments for infections associated with antibiotic resistance. Destiny Pharma's focus on unique mechanisms of action for its XF series presents potential solutions in addressing the growing global healthcare challenge of drug-resistant bacteria.

Biotronics3D, based in London, develops and markets advanced software applications for the diagnostic imaging industry. The company offers a range of products, including the 3Dnet Suite, which is designed for clinical data analysis, and specialized tools such as 3Dnet Colon for virtual colonoscopy and 3Dnet Vessel, which identifies vascular anomalies like aneurysms and stenosis. Biotronics3D's flagship product, the 3Dnet Enterprise Suite, is notable for its FDA 510K market clearance and CE marking, ensuring compliance with regulatory standards. The company focuses on enhancing healthcare by transforming diagnostic data into actionable information available at the point of care. Established in 2004, Biotronics3D is ISO 13485:2003 certified, reflecting its commitment to quality in medical software development.

CyDen is a British health and beauty company that specializes in the development and manufacturing of intense pulsed light (IPL) hair removal devices for home use. The company focuses on providing effective solutions for achieving smooth, hair-free skin by utilizing advanced IPL technology, which combines innovative design with a clinical understanding of how light interacts with skin. This approach allows customers to effectively remove hair and reduce the need for frequent shaving.

Domainex Ltd. is a biotechnology company based in Saffron Walden, United Kingdom, specializing in contract research and contract manufacturing services focused on drug discovery. Established in 2001, the company offers a comprehensive range of services including medicinal chemistry, computational chemistry, protein expression and purification, biochemical assay development, and DMPK analysis. Domainex also employs advanced technologies for hit identification and combinatorial domain hunting. The company is particularly noted for its work in developing innovative treatments for inflammatory diseases, such as DMXD-011, a small-molecule inhibitor targeting TBK1/IKKε/SIK2 for conditions like rheumatoid arthritis and lupus. Through its capabilities in biology and chemistry, Domainex aims to assist healthcare professionals in addressing complex drug discovery challenges, particularly in oncology and related fields.

PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.